Hjem › Urotelial (overgangscelle) carcinom › Massachusetts › Worcester
Urotelial (overgangscelle) carcinom kliniske forsøg i Worcester, MA
4 studier for Urotelial (overgangscelle) carcinom søger deltagere på steder i og omkring Worcester (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.
Officiel studietekst (engelsk)
Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
RekruttererFase 3
- UMass Memorial Medical Center - University Campus, Worcester
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
RekruttererFase 3
- University of Massachusetts Medical School, Worcester
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
RekruttererFase 2
- UMass Memorial Medical Center, Worcester
- University of Massachusetts Chan Medical School, Worcester
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruttererObservationsstudie
- Massive Bio SYNERGY-AI site, Worcester
Urotelial (overgangscelle) carcinom forsøg i andre byer
- Nashville, TN23 studier
- New York City, NY22 studier
- Dallas, TX18 studier
- Edison, NJ18 studier
- Houston, TX18 studier
- Los Angeles, CA17 studier
- Queens, NY15 studier
- Chicago, IL14 studier
- Arlington, VA12 studier
- San Antonio, TX11 studier
- Boston, MA11 studier
- Austin, TX10 studier
Andre studier i Worcester
- Ikke-småcellet lungecancer14 studier
- Lungecancer11 studier
- Kræft (alle typer)7 studier
- Brystkræft6 studier
- Skizofreni5 studier
- Metastatisk cancer5 studier
- Prostatakræft5 studier
- Ægstockræft5 studier
- Alvorlig depressiv lidelse5 studier
- Depression5 studier
- Akut myeloid leukæmi5 studier
- Blærecancer4 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.